A Study of LY3305677 in Participants With Obesity Or Overweight

Completed · Phase 1 · Has a placebo group

Conditions studied: Overweight, Obesity

In brief

The main purpose of this study is to learn about the safety and tolerability of LY3305677 when given to participants with obesity or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3305677 or placebo given just under the skin. For each participant, the study will last about approximately 28 weeks.

Key facts

Study ID

NCT05623839

Run by

Eli Lilly and Company

People needed

32

Starts

2022-11-16

Expected to finish

2023-06-27

Last updated by the study team

2023-07-05

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants who are overtly healthy as determined by medical evaluation
• Participants with stable weight for 3 months and body mass index of 27.0 and 50.0 kilograms per square meter (kg/m²)

You may not qualify if…

• Have history of type 1 diabetes mellitus or type 2 diabetes mellitus, ketoacidosis, or hyperosmolar state or coma

Where it is running

• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• ICON Early Phase Services — San Antonio, Texas, United States
• ICON Early Phase Services Lenexa Center — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.